Biotech · Private company
Ascletis Pharma (China) Co., Limited
Track this companyFree. Adds Ascletis Pharma (China) Co., Limited to your Dealase workspace and tells you when its record changes.
Clinical trials115 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- ASC30 tablets A1Phase 3 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
- ASC30 tabletsPhase 2 · T2DM (Type 2 Diabetes Mellitus)ClinicalTrials.gov · fetched Nov 12, 2026
- ASC30Phase 1 · Weight ManagementClinicalTrials.gov · fetched Nov 12, 2026
- ASC35 Injection B, for subcutaneous usePhase 1 · Chronic Weight ManagementClinicalTrials.gov · fetched Nov 12, 2026
- ASC36 Injection A, for subcutaneous usePhase 1 · Chronic Weight ManagementClinicalTrials.gov · fetched Nov 12, 2026
- ASC36 Injection B, for subcutaneous usePhase 1 · Chronic Weight ManagementClinicalTrials.gov · fetched Nov 12, 2026
- ASC36 tablets, for oral usePhase 1 · Chronic Weight ManagementClinicalTrials.gov · fetched Nov 12, 2026
- ASC47 +SemaglutidePhase 1 · Chronic Weight ManagementClinicalTrials.gov · fetched Nov 12, 2026
- TirzepatidePhase 1 · Chronic Weight ManagementClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or OverweightPHASE1 · RECRUITING · started Oct 13, 2026ClinicalTrials.gov NCT07893106 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or OverweightPHASE1 · RECRUITING · started Sep 28, 2026ClinicalTrials.gov NCT07893093 · fetched Nov 12, 2026
- A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesPHASE3 · RECRUITING · started Aug 31, 2026ClinicalTrials.gov NCT07743463 · fetched Nov 12, 2026
- A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 DiabetesPHASE3 · RECRUITING · started Aug 28, 2026ClinicalTrials.gov NCT07743450 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or OverweightPHASE1 · RECRUITING · started Aug 27, 2026ClinicalTrials.gov NCT07842640 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes MellitusPHASE2 · COMPLETED · started Jan 22, 2026ClinicalTrials.gov NCT07321678 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related ComorbiditiesPHASE2 · COMPLETED · started Jul 3, 2025ClinicalTrials.gov NCT07002905 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque PsoriasisPHASE1 · COMPLETED · started Jun 4, 2025ClinicalTrials.gov NCT07024602 · fetched Nov 12, 2026
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With SemaglutidePHASE1 · COMPLETED · started Apr 18, 2025ClinicalTrials.gov NCT06972992 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With ObesityPHASE1_PHASE2 · COMPLETED · started Sep 16, 2024ClinicalTrials.gov NCT06679959 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With ObesityPHASE1 · COMPLETED · started Aug 26, 2024ClinicalTrials.gov NCT06680440 · fetched Nov 12, 2026